Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
89bio (ETNB) Stock Price & Analysis
757 Followers
ETNB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $18.30
Previous Close$8.35
Volume934.65K
Average Volume (3M)1.00M
Market Cap
$821.51M
Enterprise Value$286.52M
Total Cash (Recent Filing)$562.29M
Total Debt (Recent Filing)$27.30M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 08, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding98,383,998
10 Day Avg. Volume1,288,468
30 Day Avg. Volume1,001,382
Standard Deviation0.25
R-Squared0.05
Alpha-0.00346
Financial Highlights & Ratios
Price to Book (P/B)1.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.79
Forecast
1Y Price Target
$28.50Price Target Upside241.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
89bio News
Bulls Say, Bears Say
Bulls Say
Clinical DataPatients treated with pegozafermin showed statistically significant improvements across key liver health markers at Week 48.
Market ResearchETNB presented encouraging new market research of pegoza's commercial opportunity, if approved.
Ongoing TrialsThe initiation of the Phase 3 ENLIGHTEN-Cirrhosis study is considered a major achievement.
Bears Say
Clinical TrialsRisks include potential clinical trial failure and challenges in securing regulatory approvals.
CompetitionConcerns over competition in the fatty liver disease space and commercial unknowns ahead of the first-to-market MASH launch have weighed sentiment.
Market SentimentConcerns over competition in the fatty liver disease space and commercial unknowns ahead of the first-to-market MASH launch have weighed sentiment.
---
Ownership Overview
22.21% Insiders
17.94% Mutual Funds
11.58% Other Institutional Investors
48.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $6.58 and its highest was $18.30 in the past 12 months.
What is 89bio’s market cap?
Currently, no data Available
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Aug 08, 2024 which is in 18 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on May 09, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.455 by -$0.085.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -$0.56.
How many shares outstanding does 89bio have?
89bio has 98,383,995 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.455. Following the earnings report the stock price went down -4.391%.
Which hedge fund is a major shareholder of 89bio?
Among the largest hedge funds holding 89bio’s share is RA Capital Management. It holds 89bio’s shares valued at 149M.
---
89bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (241.32% Upside)
$28.50 (241.32% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.98%
12-Months-Change
Fundamentals
Return on Equity
-34.51%
Trailing 12-Months
Asset Growth
16.79%
Trailing 12-Months
Company Description
89bio
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
---
ETNB Stock 12 Month Forecast
Average Price Target
$28.50
▲(241.32% Upside)
Technical Analysis
Seres Therapeutics
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Sorrento Therapeutics
―
Best Analysts Covering ETNB
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+80.01%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +80.01% per trade.
---